chr15-73702575-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001024736.2(CD276):c.400G>A(p.Val134Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000647 in 1,608,386 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V134A) has been classified as Uncertain significance.
Frequency
Consequence
NM_001024736.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CD276 | NM_001024736.2 | c.400G>A | p.Val134Ile | missense_variant | 3/10 | ENST00000318443.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CD276 | ENST00000318443.10 | c.400G>A | p.Val134Ile | missense_variant | 3/10 | 2 | NM_001024736.2 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152198Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000455 AC: 11AN: 241838Hom.: 0 AF XY: 0.0000303 AC XY: 4AN XY: 131844
GnomAD4 exome AF: 0.0000563 AC: 82AN: 1456070Hom.: 0 Cov.: 34 AF XY: 0.0000539 AC XY: 39AN XY: 724222
GnomAD4 genome AF: 0.000144 AC: 22AN: 152316Hom.: 0 Cov.: 33 AF XY: 0.000121 AC XY: 9AN XY: 74474
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 03, 2023 | The c.400G>A (p.V134I) alteration is located in exon 3 (coding exon 2) of the CD276 gene. This alteration results from a G to A substitution at nucleotide position 400, causing the valine (V) at amino acid position 134 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at